Ron Renaud

President and Chief Executive Officer; formerly CEO, Translate Bio, Kailera Therapeutics

Search every verified Ron Renaud interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Ron Renaud, president and chief executive officer of Kailera Therapeutics, discussed the company's work on GLP-1-based medicines for obesity in a January 2026 podcast appearance. He said he was initially drawn to the company's lead program, rebupetide, a dual GLP-1/GIP agonist injectable, after seeing data presented at the 2024 ADA meetings that showed high-teens percentage weight loss from baseline at a dose less than half of that used by Eli Lilly. Renaud described the market as still in its early stages, stating that the price-times-volume equation would remain positive for the industry for the foreseeable future and that multiple tools would be needed to help patients maintain healthy weight. In a 2018 podcast appearance, Renaud, then CEO of Translate Bio, discussed the company's development of messenger RNA therapies, initially focused on cystic fibrosis and OTC deficiency. He described the design of the company's lipid nanoparticle delivery vehicle to be mucopenetrating, citing preclinical research in a rat model with a knocked-out CFTR gene. He also emphasized the importance of company culture, saying that a winning culture, focus on patients, and letting data drive decisions were central to his approach.